Send to

Choose Destination

See 1 citation found by title matching your search:

See comment in PubMed Commons below
Pediatr Blood Cancer. 2011 Mar;56(3):474-6. doi: 10.1002/pbc.22839.

Prevalence of advanced bone age in a cohort of patients who received cis-retinoic acid for high-risk neuroblastoma.

Author information

  • 1Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA.

Erratum in

  • Pediatr Blood Cancer. 2013 Jul;60(7):1244. Moab, Sogol Mostoufi [corrected to Mostoufi, Sogol Moab].


In the last decade, 13-cis-retinoic acid (13-cis-RA) has been added to the treatment of patients with high-risk neuroblastoma. In survivors of neuroblastoma, short stature is consistently observed. Causes include growth hormone deficiency and poor growth of irradiated long bones. Within the survivorship program at CHOP, we have observed that a number of these patients also have advanced bone ages. Children treated with 13-cis-RA are at risk for advanced bone age that may dramatically impact their linear growth. Ongoing evaluation is necessary to examine the effect of 13-cis-RA on final adult height and to inform clinical practice in this cohort.

© 2010 Wiley-Liss, Inc.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Write to the Help Desk